TOFANI, LORENZO
TOFANI, LORENZO
Dipartimento di Medicina dei sistemi
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
2023-01-01 Campione, E; Lambiase, S; Gaeta Shumak, R; Galluzzo, M; Lanna, C; Costanza, G; Borselli, C; Artosi, F; Cosio, T; Tofani, L; Dattola, A; Di Daniele, F; Bianchi, L
AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks
2026-03-13 Mortato, E; Talamonti, M; Savastano, L; Marcelli, L; Tofani, L; Gneo, V; Marrapodi, D; Ingrosso, Mr; Bianchi, L; Galluzzo, M
Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real-Life Study
2025-06-01 Mortato, E; Talamonti, M; Paganini, C; Belcastro, A; Tofani, L; Bianchi, L; Galluzzo, M
Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report
2024-01-01 Galluzzo, M; Tofani, L; Spelta, S; Talamonti, M; Micera, A; Bianchi, L; Coassin, M; Bonini, S; Di Zazzo, A
Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year Study
2025-01-01 Mortato, E; Marcelli, L; Tofani, L; Belcastro, A; Talamonti, M; Paganini, C; Di Raimondo, C; Bianchi, L; Galluzzo, M
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks
2023-01-01 Galluzzo, M; Marcelli, L; Vellucci, L; Paganini, C; Maffei, V; Tofani, L; Belcastro, A; Bianchi, L; Talamonti, M
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice
2024-01-01 Paganini, C; Spelta, S; Tofani, L; Talamonti, M; Bianchi, L; Coassin, M; Di Zazzo, A; Galluzzo, M
Predictive Factors of Super-Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real-World Monocentric Study
2026-01-01 Mortato, E; Talamonti, M; Paganini, C; Belcastro, A; Tofani, L; Bianchi, L; Galluzzo, M
Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies
2025-01-01 Paganini, C; Mortato, E; Tofani, L; Belcastro, A; Talamonti, M; Di Raimondo, C; Bianchi, L; Galluzzo, M
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study
2022-04-06 Caldarola, G; Galluzzo, M; Bernardini, N; Calabrese, L; Grimaldi, M; Moretta, G; Pagnanelli, G; Shumak, Rg; Talamonti, M; Tofani, L; Pallotta, S; Peris, K; Potenza, C; De Simone, C; Campione, E
| Data di pubblicazione | Titolo | Autore(i) | Tipo | File |
|---|---|---|---|---|
| 1-gen-2023 | A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients | Campione, E; Lambiase, S; Gaeta Shumak, R; Galluzzo, M; Lanna, C; Costanza, G; Borselli, C; Artosi, F; Cosio, T; Tofani, L; Dattola, A; Di Daniele, F; Bianchi, L | Articolo su rivista | |
| 13-mar-2026 | AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks | Mortato, E; Talamonti, M; Savastano, L; Marcelli, L; Tofani, L; Gneo, V; Marrapodi, D; Ingrosso, Mr; Bianchi, L; Galluzzo, M | Articolo su rivista | |
| 1-giu-2025 | Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real-Life Study | Mortato, E; Talamonti, M; Paganini, C; Belcastro, A; Tofani, L; Bianchi, L; Galluzzo, M | Articolo su rivista | |
| 1-gen-2024 | Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report | Galluzzo, M; Tofani, L; Spelta, S; Talamonti, M; Micera, A; Bianchi, L; Coassin, M; Bonini, S; Di Zazzo, A | Articolo su rivista | |
| 1-gen-2025 | Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year Study | Mortato, E; Marcelli, L; Tofani, L; Belcastro, A; Talamonti, M; Paganini, C; Di Raimondo, C; Bianchi, L; Galluzzo, M | Articolo su rivista | |
| 1-gen-2023 | Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks | Galluzzo, M; Marcelli, L; Vellucci, L; Paganini, C; Maffei, V; Tofani, L; Belcastro, A; Bianchi, L; Talamonti, M | Articolo su rivista | |
| 1-gen-2024 | Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice | Paganini, C; Spelta, S; Tofani, L; Talamonti, M; Bianchi, L; Coassin, M; Di Zazzo, A; Galluzzo, M | Articolo su rivista | |
| 1-gen-2026 | Predictive Factors of Super-Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real-World Monocentric Study | Mortato, E; Talamonti, M; Paganini, C; Belcastro, A; Tofani, L; Bianchi, L; Galluzzo, M | Articolo su rivista | |
| 1-gen-2025 | Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies | Paganini, C; Mortato, E; Tofani, L; Belcastro, A; Talamonti, M; Di Raimondo, C; Bianchi, L; Galluzzo, M | Articolo su rivista | |
| 6-apr-2022 | Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study | Caldarola, G; Galluzzo, M; Bernardini, N; Calabrese, L; Grimaldi, M; Moretta, G; Pagnanelli, G; Shumak, Rg; Talamonti, M; Tofani, L; Pallotta, S; Peris, K; Potenza, C; De Simone, C; Campione, E | Articolo su rivista |